Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 food-effect crossover study of JNJ-64417184 tablets in healthy volunteers
NL-OMON48166Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64417184 in respiratory syncytial virus disease (RSV), sponsored by Janssen Pharmaceutical. Primary endpoint: Effect of food conditions on single-dose pharmacokinetics of JNJ-64417184. Started Oct 2019; status: completed.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON48166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48166.